Skip to main content
On Our Radar

German Biotech Initiates Phase 1b Clinical Trial of Synucleinopathy Treatment

By January 4, 2021May 26th, 2022No Comments

German Biotech Initiates Phase 1b Clinical Trial of Synucleinopathy Treatment 

MODAG, a German biotechnology company, announced that it would begin an in-patient clinical trial of anle138b, a disease-modifying treatment for synucleinopathies such as multiple system atrophy (MSA) and Parkinson’s disease (PD). 

The company completed a clinical trial of anle138b in healthy volunteers in August 2020, in which it demonstrated excellent safety and tolerability. The newly initiated in-patient trial, supported by a grant from The Michael J. Fox Foundation for Parkinson’s Research, will study the safety, tolerability, and pharmacokinetics of anle138b in patients with PD, and will allow researchers to establish an optimal dosing schedule for use in future studies.  

Anle138b is a small molecule that binds to and prevents the accumulation of alpha-synuclein. In pre-clinical trials it was shown to halt disease progression in animal models of MSA and PD. 


CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.